The invention relates to an intravaginal drug delivery device for hormonal contraception with prevention/reduction of intermenstrual bleeding and menopausal cycle disorders. The intravaginal drug delivery device includes estriol or a precursor of this compound and a progestogen or a precursor thereof.

The invention relates to an intravaginal drug delivery device for hormonal contraception with prevention/reduction of intermenstrual bleeding and menopausal cycle disorders. The intravaginal drug delivery device includes estriol or a precursor of this compound and a progestogen or a precursor thereof.

A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.

One aspect of the invention provides a method of contraception by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). The MIS can be produced endogenously in the subject by a vector, where the vector comprises a polynucletide encoding a recombinant MIS protein. In some embodiments, the contraception is permanent and only requires administration of the composition once. Another aspect of the invention relates to a method of preserving an ovarian reserve, the method comprising administering to a female subject a composition comprising MIS or an inducible vector that comprises a polynucleotide encoding a recombinant MIS protein.

It is provided a vaginal ring comprising a drug-loaded core comprising a progestogenic steroid compound, a estrogenic steroid compound, and an EVA copolymer having a vinyl acetate content from 25 to 35 wt. %, wherein the progestogenic steroid is dissolved in the core material in a relatively low degree of supersaturation; and a non-medicated outer layer of EVA copolymer having a vinyl acetate content from 5 to 15 wt. %; which is stable under storage at room temperature for at least 12 months. It is also provided a process for the preparation of the vaginal ring disclosed above.

It is provided a vaginal ring comprising a drug-loaded core comprising a progestogenic steroid compound, a estrogenic steroid compound, and an EVA copolymer having a vinyl acetate content from 25 to 35 wt. %, wherein the progestogenic steroid is dissolved in the core material in a relatively low degree of supersaturation; and a non-medicated outer layer of EVA copolymer having a vinyl acetate content from 5 to 15 wt. %; which is stable under storage at room temperature for at least 12 months. It is also provided a process for the preparation of the vaginal ring disclosed above.

Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.

Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.

The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit comprising: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable excipients;
the solid dosage unit comprising at least 100 g of the estetrol component; and wherein the solid dosage unit can be obtained by a process that comprises compressing a dry blend of estetrol particles and one or more pharmaceutically acceptable excipients into a solid dosage unit.

The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.